Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a


Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului



Yüklə 4,39 Mb.
səhifə338/381
tarix07.01.2022
ölçüsü4,39 Mb.
#80899
1   ...   334   335   336   337   338   339   340   341   ...   381
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A10BD02 COMBINATII COMPR. FILM. 2,5 mg/400 mg

(GLIBENCLAMIDUM +

METFORMINUM)

GLIBOMET(R) 2,5 mg/400 mg LAB. GUIDOTTI SPA
A10BD02 COMBINATII COMPR. FILM. 400 mg + 2.5 mg

(GLIBENCLAMIDUM +

METFORMINUM)

GLIFORMIN 400 mg + 2.5 mg LABORMED PHARMA SA


A10BD02 COMBINATII CAPS. 400 mg + 2.5 mg

(GLIBENCLAMIDUM +

METFORMINUM)

BIDIAB 400 mg + 2.5 mg ARENA GROUP SA


A10BD02 COMBINATII COMPR. FILM. 500 mg/2.5 mg

(GLIBENCLAMIDUM +

METFORMINUM)

GLUCOVANCE(R) 500 mg/2.5 mg 500 mg/2.5 mg MERCK SANTE


A10BD02 COMBINATII COMPR. FILM. 500 mg/5 mg

(GLIBENCLAMIDUM +

METFORMINUM)

GLUCOVANCE(R) 500 mg/5 mg 500 mg/5 mg MERCK SANTE

________________________________________________________________________________
______________________________________________________________________________

| 809 |A10BD03| COMBINATII (ROSIGLITAZONUM + | Protocol: A026E |

| | | METFORMINUM)*** | |

|_______|_______|____________________________________________|_________________|


________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A10BD03 COMBINATII COMPR. FILM. 1 mg/500 mg

(ROSIGLITAZONUM +

METFORMINUM)

AVANDAMET 1 mg/500 mg 1 mg/500 mg SMITHKLINE BEECHAM PLC
A10BD03 COMBINATII COMPR. FILM. 2 mg/1000 mg

(ROSIGLITAZONUM +

METFORMINUM)

AVANDAMET 2 mg/1000 mg 2 mg/1000 mg SMITHKLINE BEECHAM PLC


A10BD03 COMBINATII COMPR. FILM. 2 mg/500 mg

(ROSIGLITAZONUM +

METFORMINUM)

AVANDAMET 2 mg/500 mg 2 mg/500 mg SMITHKLINE BEECHAM PLC


A10BD03 COMBINATII COMPR. FILM. 4 mg/1000 mg

(ROSIGLITAZONUM +

METFORMINUM)

AVANDAMET 4 mg/1000 mg 4 mg/1000 mg SMITHKLINE BEECHAM PLC

________________________________________________________________________________
______________________________________________________________________________

| 810 |A10BD04| COMBINATII (ROSIGLITAZONUM + | Protocol: A027E |

| | | GLIMEPIRIDUM)*** | |

|_______|_______|____________________________________________|_________________|


________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A10BD04 COMBINATII COMPR. FILM. 4 mg/4 mg

(ROSIGLITAZONUM +

GLIMEPIRIDUM)

AVAGLIM 4 mg/4 mg 4 mg/4 mg SMITHKLINE BEECHAM PLC
A10BD04 COMBINATII COMPR. FILM. 8 mg/4 mg

(ROSIGLITAZONUM +

GLIMEPIRIDUM)

AVAGLIM 8 mg/4 mg 8 mg/4 mg SMITHKLINE BEECHAM PLC

________________________________________________________________________________
______________________________________________________________________________

| 811 |A10BD05| COMBINATII (PIOGLITAZONUM + METFORMINUM)***| Protocol: A025E |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A10BD05 COMBINATII COMPR. FILM. 15 mg/850 mg

(PIOGLITAZONUM +

METFORMINUM)

COMPETACT 15 mg/850 mg TAKEDA GLOBAL RESEARCH AND

DEVELOPMENT CENTRE LTD

________________________________________________________________________________
______________________________________________________________________________

| 812 |A10BF01| ACARBOSUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A10BF01 ACARBOSUM COMPR. 100 mg

GLUCOBAY(R) 100 100 mg BAYER HEALTHCARE AG
A10BF01 ACARBOSUM COMPR. 50 mg

GLUCOBAY(R) 50 50 mg BAYER HEALTHCARE AG

________________________________________________________________________________
______________________________________________________________________________

| 813 |A10BG02| ROSIGLITAZONUM*** | Protocol: A020E |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A10BG02 ROSIGLITAZONUM COMPR. FILM. 4 mg

AVANDIA 4 mg 4 mg SMITHKLINE BEECHAM PLC

________________________________________________________________________________


______________________________________________________________________________

| 814 |A10BG03| PIOGLITAZONUM*** | Protocol: A020E |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A10BG03 PIOGLITAZONUM COMPR. 15 mg

ACTOS 15 mg 15 mg TAKEDA GLOBAL RESEARCH AND

DEVELOPMENT CENTRE LTD


A10BG03 PIOGLITAZONUM COMPR. 30 mg

ACTOS 30 mg 30 mg TAKEDA GLOBAL RESEARCH AND

DEVELOPMENT CENTRE LTD
A10BG03 PIOGLITAZONUM COMPR. 45 mg

ACTOS 45 mg 45 mg TAKEDA GLOBAL RESEARCH AND

DEVELOPMENT CENTRE LTD

________________________________________________________________________________


______________________________________________________________________________

| 815 |A10BH01| SITAGLIPTINUM*** | Protocol: A022E |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A10BH01 SITAGLIPTINUM COMPR. FILM. 100 mg

JANUVIA 100 mg 100 mg MERCK SHARP & DOHME LTD.

________________________________________________________________________________


______________________________________________________________________________

| 816 |A10BX02| REPAGLINIDUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A10BX02 REPAGLINIDUM COMPR. 0.5 mg

NOVONORM 0.5 mg 0.5 mg NOVO NORDISK A/S
A10BX02 REPAGLINIDUM COMPR. 1 mg

NOVONORM 1 mg 1 mg NOVO NORDISK A/S


A10BX02 REPAGLINIDUM COMPR. 2 mg

NOVONORM 2 mg 2 mg NOVO NORDISK A/S

________________________________________________________________________________
______________________________________________________________________________

| 817 |A10BX04| EXENATIDUM*** | Protocol: A028E |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A10BX04 EXENATIDUM SOL. INJ. IN STILOU 10 µg/doza

INJECTOR PREUMPLUT

BYETTA 10 µg/doza 10 µg/doza ELI LILLY NEDERLAND BV


A10BX04 EXENATIDUM SOL. INJ. IN STILOU 5 µg/doza

INJECTOR PREUMPLUT

BYETTA 5 µg/doza 5 µg/doza ELI LILLY NEDERLAND BV

________________________________________________________________________________


______________________________________________________________________________

| 818 |A11DA03| BENFOTIAMINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A11DA03 BENFOTIAMINUM DRAJ. 50 mg

BENFOGAMMA 50 mg WORWAG PHARMA GMBH & CO.

KG

________________________________________________________________________________


______________________________________________________________________________

| 819 |A11DBN1| COMBINATII** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A11DBN1 COMBINATII CAPS. MOI

MILGAMMA(R) N WORWAG PHARMA GMBH & CO.

KG

A11DBN1 COMBINATII SOL. INJ.



MILGAMMA(R) N WORWAG PHARMA GMBH & CO.

KG

________________________________________________________________________________


______________________________________________________________________________

| 820 |H04AA01| GLUCAGONUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H04AA01 GLUCAGONUM PULB. + SOLV. PT. SOL. 1 mg

INJ.

GLUCAGEN HYPOKIT 1 mg 1 mg NOVO NORDISK A/S



________________________________________________________________________________
SUBLISTA C2 - P6: PROGRAMUL NAŢIONAL DE HEMOFILIE, TALASEMIE ŞI ALTE BOLI RARE. P6.1: HEMOFILIE ŞI TALASEMIE
______________________________________________________________________________

| 827 |V03AC01| DEFEROXAMINUM**(3) | Protocol: V001D |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

V03AC01 DEFEROXAMINUM LIOF. PT. SOL. 500 mg

INJ./PERF.

DESFERAL 500 mg NOVARTIS PHARMA GMBH

________________________________________________________________________________
______________________________________________________________________________

| 828 |V03AC03| DEFERASIROXUM**** | Protocol: V002D |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

V03AC03 DEFERASIROXUM COMPR. DISP. 125 mg

EXJADE 125 mg 125 mg NOVARTIS EUROPHARM LTD.
V03AC03 DEFERASIROXUM COMPR. DISP. 250 mg

EXJADE 250 mg 250 mg NOVARTIS EUROPHARM LTD.


V03AC03 DEFERASIROXUM COMPR. DISP. 500 mg

EXJADE 500 mg 500 mg NOVARTIS EUROPHARM LTD.

________________________________________________________________________________
SUBLISTA C2 - P6: PROGRAMUL NAŢIONAL DE HEMOFILIE, TALASEMIE ŞI ALTE BOLI RARE. P6.2: EPIDERMOLIZA BULOASĂ
______________________________________________________________________________

| 830 |D06AA04| TETRACYCLINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

D06AA04 TETRACYCLINUM UNGUENT 3,00%

TETRACICLINA CLORHIDRAT 3% ANTIBIOTICE SA

________________________________________________________________________________


______________________________________________________________________________

| 831 |D06AX01| ACIDUM FUSIDICUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

D06AX01 ACIDUM FUSIDICUM CREMA 2,00%

FUCIDIN(R) 2% LEO PHARMACEUTICAL

PRODUCTS
D06AX01 ACIDUM FUSIDICUM UNGUENT 2,00%

FUCIDIN(R) 2% LEO PHARMACEUTICAL

PRODUCTS


________________________________________________________________________________
______________________________________________________________________________

| 832 |D06BA01| SULFADIAZINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

D06BA01 SULFADIAZINUM CREMA 1,00%

DERMAZIN(R) 1% 1% LEK PHARMACEUTICALS D.D.

________________________________________________________________________________


______________________________________________________________________________

| 833 |D07CA01| COMBINATII (ACIDUM FUSIDICUM + | Protocol: D001L |

| | | HYDROCORTISONUM) | |

|_______|_______|____________________________________________|_________________|


________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

D07CA01 COMBINATII (ACIDUM CREMA

FUSIDICUM +

HYDROCORTISONUM)

FUCIDIN(R) H LEO PHARMACEUTICAL

PRODUCTS


________________________________________________________________________________
______________________________________________________________________________

| 834 |D07CC01| COMBINATII | Protocol: D001L |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

D07CC01 COMBINATII CREMA

BELOGENT A & G MED TRADING S.R.L.

DIPROGENTA(R) SCHERING PLOUGH EUROPE

TRIDERM(R) SCHERING PLOUGH EUROPE
D07CC01 COMBINATII UNGUENT

BELOGENT A & G MED TRADING S.R.L.

DIPROGENTA(R) SCHERING PLOUGH EUROPE

TRIDERM SCHERING PLOUGH EUROPE

________________________________________________________________________________
______________________________________________________________________________

| 836 |J01AA07| TETRACYCLINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01AA07 TETRACYCLINUM CAPS. 250 mg

TETRACICLINA 250 mg 250 mg EUROPHARM SA

TETRACICLINA SANDOZ 250 mg 250 mg SANDOZ SRL

________________________________________________________________________________
______________________________________________________________________________

| 838 |N03AB02| PHENYTOINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

N03AB02 PHENYTOINUM COMPR. 100 mg

FENITOIN 100 mg 100 mg GEDEON RICHTER ROMANIA SA
N03AB02 PHENYTOINUM SOL. INJ. 50 mg/ml

PHENHYDAN(R) SOLUTIE 50 mg/ml DESITIN

INJECTABILA

________________________________________________________________________________


SUBLISTA C2 - P6: PROGRAMUL NAŢIONAL DE HEMOFILIE, TALASEMIE ŞI ALTE BOLI RARE. P6.3: HIPERTENSIUNEA PULMONARĂ
______________________________________________________________________________

| 839 |C02KX01| BOSENTANUM** | Protocol: CI01I |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

C02KX01 BOSENTANUM COMPR. FILM. 125 mg

TRACLEER 125 mg 125 mg ACTELION REGISTRATION LTD.
Bosentanum este un medicament care nu trebuie administrat la gravide. Sarcina trebuie evitată timp de trei luni după întreruperea tratamentului.
________________________________________________________________________________
______________________________________________________________________________

| 840 |G04BE03| SILDENAFILUM** | Protocol: CI01I |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

G04BE03 SILDENAFILUM COMPR. FILM. 20 mg

REVATIO 20 mg 20 mg PFIZER LTD.

________________________________________________________________________________


SUBLISTA C2 - P6: PROGRAMUL NAŢIONAL DE HEMOFILIE, TALASEMIE ŞI ALTE BOLI RARE. P6.4: MUCOVISCIDOZA
______________________________________________________________________________

| 841 |J01FA09| CLARITHROMYCINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01FA09 CLARITHROMYCINUM GRAN. PT. SUSP. ORALA 125 mg/5 ml

FROMILID(R) 125 mg/5 ml 125 mg/5 ml KRKA D.D.

KLABAX 125 mg/5 ml 125 mg/5 ml TERAPIA S.A.

KLACID(R) 125 mg/5 ml ABBOTT SPA

LEKOKLAR 125 mg/5 ml 125 mg/5 ml SANDOZ S.R.L.


J01FA09 CLARITHROMYCINUM COMPR. FILM. 250 mg

CLAR 250 250 mg MEDICAROM GROUP S.R.L.

CLARITROMICINA 250 mg 250 mg OZONE LABORATORIES LTD.

FROMILID 250 250 mg KRKA D.D. NOVO MESTO

KLABAX 250 mg 250 mg TERAPIA S.A.

KLACID(R) 250 mg ABBOTT SPA

KLERIMED(R) 250 250 mg MEDOCHEMIE LTD.

LEKOKLAR(R) 250 mg 250 mg LEK PHARMACEUTICALS D.D.


J01FA09 CLARITHROMYCINUM GRAN. PT. SUSP. ORALA 250 mg/5 ml

KLABAX 250 mg/5 ml 250 mg/5 ml TERAPIA S.A.

LEKOKLAR 250 mg/5 ml 250 mg/5 ml SANDOZ SRL
J01FA09 CLARITHROMYCINUM COMPR. FILM. 500 mg

CLAR 500 500 mg MEDICAROM GROUP S.R.L.

CLARITROMICINA 500 mg 500 mg OZONE LABORATORIES LTD.

FROMILID 500 500 mg KRKA D.D. NOVO MESTO

KLABAX 500 mg 500 mg TERAPIA S.A.

KLERIMED(R) 500 500 mg MEDOCHEMIE LTD.

LEKOKLAR(R) 500 mg 500 mg LEK PHARMACEUTICALS D.D.
J01FA09 CLARITHROMYCINUM COMPR. FILM. ELIB. 500 mg

MODIF.


KLABAX MR 500 mg 500 mg TERAPIA S.A.

LEKOKLAR XL 500 mg 500 mg LEK PHARMACEUTICALS D.D.


J01FA09 CLARITHROMYCINUM COMPR. FILM. ELIB. PREL 500 mg

FROMILID(R) UNO 500 mg KRKA D.D.

KLACID SR 500 mg ABBOTT LABORATORIES LTD.
J01FA09 CLARITHROMYCINUM LIOF. PT. SOL. PERF. 500 mg

KLACID I.V. 500 mg ABBOTT LABORATORIES LTD.

________________________________________________________________________________
______________________________________________________________________________

| 842 |J01GB01| TOBRAMYCINUM** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01GB01 TOBRAMYCINUM SOL. INHAL. 300 mg/5 ml

TOBI(R) 300 mg/5 ml NOVARTIS PHARMA GMBH
Prescriere limitată: Infecţii cu agent patogen sensibil confirmat pentru acest tip de antibiotic.
________________________________________________________________________________
______________________________________________________________________________

| 843 |R05CB13| DORNAZA ALFA** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

R05CB13 DORNAZA ALFA SOL. INHAL. 1 mg/ml

PULMOZYME 1 mg/ml ROCHE ROMANIA S.R.L.

________________________________________________________________________________


SUBLISTA C2 - P6: PROGRAMUL NAŢIONAL DE HEMOFILIE, TALASEMIE ŞI ALTE BOLI RARE. P6.5: BOLI NEUROLOGICE DEGENERATIVE/INFLAMATORII (POLIRADICULONEVRITA PRIMITIVĂ, POLINEUROPATIE INFLAMATORIE CRONICĂ DEMIELINIZANTĂ, SCLEROZA LATERALĂ AMIOTROFICĂ) ŞI MIASTENIA GRAVIS
______________________________________________________________________________

| 844 |N07XX02| RILUZOLUM** | Protocol: N024G |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

N07XX02 RILUZOLUM COMPR. FILM. 50 mg

RILUTEK 50 mg 50 mg AVENTIS PHARMA SA

________________________________________________________________________________


SUBLISTA C2 - P6: PROGRAMUL NAŢIONAL DE HEMOFILIE, TALASEMIE ŞI ALTE BOLI RARE. P6.6: OSTEOGENEZA IMPERFECTA
______________________________________________________________________________

| 846 |M05BA03| ACIDUM PAMIDRONICUM | Protocol: M002Q |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

M05BA03 ACIDUM PAMIDRONICUM LIOF. + SOLV. PT. SOL. 15 mg

PERF.

AREDIA(R) 15 mg 15 mg NOVARTIS PHARMA GMBH


M05BA03 ACIDUM PAMIDRONICUM CONC. PT. SOL. PERF. 15 mg/ml

PAMIDRONAT TORREX 15 mg/ml TORREX CHIESI PHARMA GMBH


M05BA03 ACIDUM PAMIDRONICUM LIOF. PT. SOL. PERF. 30 mg

I.V.


PAMIRED 30 30 mg DR. REDDY'S LABORATORIES
M05BA03 ACIDUM PAMIDRONICUM LIOF. PT. SOL. PERF. 60 mg

I.V.


PAMIRED 60 60 mg DR. REDDY'S LABORATORIES

________________________________________________________________________________


SUBLISTA C2 - P6: PROGRAMUL NAŢIONAL DE HEMOFILIE, TALASEMIE ŞI ALTE BOLI RARE. P6.7: SINDROM PRADER WILLI
______________________________________________________________________________

| 847 |H01AC01| SOMATROPINUM** | Protocol: H011Q |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H01AC01 SOMATROPINUM SOL. INJ. 10 mg/1.5 ml

NORDITROPIN 10 mg/1.5 ml NOVO NORDISK A/S

SIMPLEX x 10 mg/1,5 ml


H01AC01 SOMATROPINUM SOL. INJ. 10 mg/2 ml

NUTROPINAq 10 mg/2 ml 10 mg/2 ml IPSEN LIMITED


H01AC01 SOMATROPINUM SOL. INJ. 3,3 mg/ml

OMNITROPE 3,3 mg/ml 3,3 mg/ml SANDOZ GMBH


H01AC01 SOMATROPINUM LIOF. + SOLV. PT. SOL. 4 mg (12 ui)

INJ.


ZOMACTON 4 mg (12 ui) FERING GMBH
H01AC01 SOMATROPINUM PULB. + SOLV. PT. SOL. 5.3 mg/ml (16 ui)

INJ.


GENOTROPIN(R) 16 ui (5.3 mg) 5.3 mg/ml (16 ui) PFIZER EUROPE MA EEIG
H01AC01 SOMATROPINUM SOL. INJ. 5 mg/1.5 ml

NORDITROPIN 5 mg/1.5 ml NOVO NORDISK A/S

SIMPLEX x 5 mg/1.5 ml

________________________________________________________________________________


SUBLISTA C2 - P6: PROGRAMUL NAŢIONAL DE HEMOFILIE, TALASEMIE ŞI ALTE BOLI RARE. P6.8: BOALA FABRY
______________________________________________________________________________

| 848 |A16AB04| AGALSIDASUM BETA** | Protocol: A014E |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A16AB04 AGALSIDASUM BETA PULB. PT. CONC. PT. 35 mg

SOL. PERF.

FABRAZYME 35 mg 35 mg GENZYME EUROPE BV

________________________________________________________________________________
SUBLISTA C2 - P6: PROGRAMUL NAŢIONAL DE HEMOFILIE, TALASEMIE ŞI ALTE BOLI RARE. P6.9: BOALA POMPE
______________________________________________________________________________

| 849 |A16AB07| ALGLUCOSIDASUM ALPHA** | Protocol: A030Q |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A16AB07 ALGLUCOSIDASUM ALPHA PULB. PT. CONC. PT. 50 mg

SOL. PERF.

MYOZYME 50 mg 50 mg GENZYME EUROPE B.V.

________________________________________________________________________________
SUBLISTA C2 - P7: PROGRAMUL NAŢIONAL DE BOLI ENDOCRINE. TRATAMENTUL MEDICAMENTOS AL BOLNAVILOR CU OSTEOPOROZĂ, GUŞĂ DATORATĂ CARENŢEI DE IOD ŞI PROLIFERĂRII MALIGNE
______________________________________________________________________________

| 850 |A11CC02| DIHYDROTACHYSTEROLUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A11CC02 DIHYDROTACHYSTEROLUM PICATURI ORALE-SOL 0.1 mg/ml

TACHYSTIN 0.1 mg/ml CHAUVIN ANKERPHARM GMBH
A11CC02 DIHYDROTACHYSTEROLUM PICATURI ORALE-SOL. 1 mg/ml

A.T. 10(R) 1 mg/ml MERCK KGAA

________________________________________________________________________________
______________________________________________________________________________

| 851 |A11CC03| ALFACALCIDOLUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A11CC03 ALFACALCIDOLUM CAPS. MOI 0.25 µg

ALPHA D3 0,25 µg 0.25 µg TEVA PHARMACEUTICALS SRL
A11CC03 ALFACALCIDOLUM CAPS. MOI 0.50 µg

ALPHA D3 0.50 µg 0.50 µg TEVA PHARMACEUTICALS

S.R.L.

________________________________________________________________________________


______________________________________________________________________________

| 852 |A11CC04| CALCITRIOLUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A11CC04 CALCITRIOLUM CAPS. MOI 0.25 µg

ROCALTROL 0.25 µg ROCHE ROMANIA S.R.L.

________________________________________________________________________________


______________________________________________________________________________

| 853 |G03CA03| ESTRADIOLUM | |

|_______|_______|____________________________________________|_________________|
Prescriere limitată: Utilizat în simptomele caracteristice post-menopauzei,


Yüklə 4,39 Mb.

Dostları ilə paylaş:
1   ...   334   335   336   337   338   339   340   341   ...   381




Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©muhaz.org 2024
rəhbərliyinə müraciət

gir | qeydiyyatdan keç
    Ana səhifə


yükləyin